Lung Fibrosis after Chemotherapy Containing Docetaxel in a Patient Treated for Breast Cancer by A. Hassouni et al.
A. Hassouni et al., (2015) Lung Fibrosis after Chemotherapy Containing Docetaxel in a Patient Treated For Breast Cancer. Int J Cancer Stud Res. 4(4), 82-85
82
http://scidoc.org/IJCR.php
International Journal of Cancer Studies & Research (IJCR)
 ISSN:2167-9118
Lung Fibrosis after Chemotherapy Containing Docetaxel in a Patient Treated for Breast Cancer
          Case Report
A. Hassouni1*, Z. Youbi1, N. Tawfiq1, Z. Boughaleb1, N. Naqos2, A. Rachdi2, A. Taleb2, Z. Bouchbika1, N. Benchakroun1, H. Jouhadi1, S. Sahraoui1, A. 
Benider1 
1 MOHAMMED VI Cancer treatment Center, Radiation Oncology Department, Ibn Rochd University Hospital, Morocco.
2 MOHAMMED VI Cancer treatment Center, Medical Oncology Department, Ibn Rochd University Hospital, Morocco.
*Corresponding Author: 
Abdeslam  HASSOUNI,
MOHAMMED VI Cancer treatment Center, Radiation Oncology De-
partment, Ibn Rochd University Hospital, Morocco.
Tel: +212670982624
E-mail: abdes.hassouni@gmail.com
Received: July 08, 2015
Accepted: August 15, 2015
Published: August 18, 2015
Citation: A. Hassouni et al., (2015) Lung Fibrosis after Chemotherapy 
Containing Docetaxel in a Patient Treated For Breast Cancer. Int J Can-
cer Stud Res. 4(4), 82-85. doi: http://dx.doi.org/10.19070/2167-9118-
1500012
Copyright: A. Hassouni© 2015. This is an open-access article distribut-
ed under the terms of  the Creative Commons Attribution License, which 
permits unrestricted use, distribution and reproduction in any medium, 
provided the original author and source are credited.
Introduction 
Docetaxel is a chemotherapeutic agent which is increasingly used 
in the treatment of  several types of  cancer including breast cancer 
[1].
Its main side effects are neutropenia, mucocutaneous hypersen-
sitivity reactions and fluid retention. Interstitial pneumotistis is 
rarely reported as a side effect in the literature. 
We report the case of  a patient with bilateral breast invasive ductal 
carcinoma who developed acute diffuse interstitial pneumotistis 
following chemotherapy containing docetaxel.
Case Report
Ms. AK is a 46 year old female with no signficant past medical his-
tory that we were consulted to evaluate for two years of  increas-
ing left breast size and progressively worsening mastodynia. Clini-
cal examination noted increased breast volume with a retracted 
nipple, skin thickening and a nodule of  7cm in diameter in the 
lower inner quadrant associated with inflammation of  the skin. 
The right breast was normal and no axillary or supraclavicular 
adenopathy were found. The biopsy of  the nodule has objectified 
infiltrating ductal carcinoma grade II SBR. The chest x-ray (Figure 
1) and abdominal ultrasound were normal. It was classified T4b-
NoMo. She received 4 cycles of  neoadjuvant chemotherapy ac-
cording to the AC60 protocol. She underwent a modified radical 
mastectomy and there was a residual tumor measuring 40 mm in 
diameter and a single axillary node was involved. She received two 
courses of  adjuvant chemotherapy according to 5FU/Navelbine 
protocol. Radiotherapy was delivered on the chest wall, axillary, 
supraclavicular lymph nodes and internal mammary chain at 50 
Gy. She finished her treatment in March 2005. Hormone recep-
tors were positive, and she was put on Tamoxifen for 5 years. 
She has been regularly monitored in the consultation. The chest 
x-ray done in August 2005 was normal. The chest x-ray done in 
November 2006 revealed a difference in transparency between 
the two lung fields, related to mastectomy without parenchymal 
lesion. The chest x-ray in October 2007 was normal.
The patient was evaluated in March 2008 for bilateral cervical-
brachial neuralgia. Bone scan objectified a hyperfixation in the 
cervical spine. MRI confirmed metastatic involvement of  D1. 
The chest x-ray was normal (Figure 2). Abdominal ultrasound 
was normal. CA 15-3 was 40.2 U/ml. She received decompressive 
radiotherapy on the cervical spine from C6 to D3, taking into ac-
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count the dose already received on the spinal cord in the anterior 
axillary lymph node areas, supraclavicular and internal mammary 
irradiation, and hormone therapy with exemestane was given. CA 
15-3 was 36.4 U/ml (down 11%) after two months of  endocrine 
therapy. Two months later, the CA 15-3 was 58.5 U/ml. A bone 
scan showed regression of  uptake on T1 and no new sites of  
uptake.
The CA 15-3 has remained at high levels despite normal im-
aging
In March 2010, she had skin thickening with orange peel on the 
lower quadrant of  the right breast associated with homolateral 
axillary adenopathies. The mammography-sonography noted dif-
fuse thickening of  the right breast. A skin biopsy found a moder-
ately differentiated CCI SBR II associated with vascular emboli. 
The staging was normal including a chest X-ray Normal. Bone 
scan did not found new sites of  uptake. The abdominopelvic and 
neck ultrasonography were normal. It was classified T4bN2M0. 
Neoadjuvant chemotherapy with docetaxel at a dose of  75 mg/ 
m2 and capecitabine at a dose of  2000mg/m2 has been started. An 
evaluation was planned after 3 cycles. The surgery was scheduled 
after regression of  inflammatory signs on the breast and of  the 
right axillary adenopathies. The first two treatments were well tol-
erated by the patient.
Fifteen days after the third treatment (21 June 2010), she was 
evaluated for major dyspnea stage IV associated with a dry cough 
and asthenia. The Chest x-ray showed bilateral diffuse interstitial 
infiltrate suggestive of  pulmonary metastatic spread. Faced with 
respiratory failure, no treatment has been decided on the oncolog-
ical plan. She was put on corticosteroid therapy of  60mg daily for 
6 days. Given the persistence of  dyspnea, corticosteroid dose was 
increased to 120mg per day orally for a period of  one week. The 
patient was seen a week later. In the absence of  respiratory func-
tion improvement metastatic lung lesions character were retained 
and no treatment was decided. Faced with respiratory failure, no 
treatment has been decided on the oncological plan. She was put 
on corticosteroid therapy to 60mg for 6 days. Given the persis-
tence of  dyspnea, the corticosteroid dose was increased to 120 
mg per day orally for a period of  one week. The administration 
of  an oxygen therapy and a high dose pf  corticosteroid followed 
by gradual regression for 2 months, have led to a complete regres-
sion of  the dyspnea. A radiological control showed the organiza-
tion of  pulmonary involvement in a visible proximal interstitial 
infiltrate on a chest CT (Figure 3).
The surgery of  the right breast was cancelled due to the inflam-
matory interstitial lung disease. The patient received radiotherapy 
to the right breast, axillary, and supraclavicular nodes at a dose of  
50 Gy from January to March 2011. She had a modified radical 
mastectomy in April 2011 in front of  the improvement of  the 
respiratory function. In the histological study, there was a chronic 
fibrous reshuffle with less than 5% of  residual tumor post-ra-
diotherapy and a single adenopathy was involved in the axillary 
dissection from 10 lymph node collected.
Hormone receptors were negative. The HercepTest was posi-
tive 3+. Herceptin was not administered because of  the risk of  
heart failure when she already had a lung injury. In August 2011, 
the patient presented bilateral cervicobrachial neuralgia with pa-
resis of  both upper limbs. MRI of  the thoracic spine revealed 
cord compression at the level of  T1 Radiotherapy was already 
issued on this site at a dose of  45 Gy in 2008. A decompressive 
laminectomy sighting was proposed. The lesion was considered a 
slowly progressive neurological level by neurosurgeons with a risk 
of  addiction to artificial respiratory ventilation after the surgery. 
Thus, surgery was deferred. An exploration of  respiratory func-
tion was performed in December 2011 to evaluate the respiratory 
risk during anesthesia. Bronchoscopy showed a normal aspect of  
the bronchi. The pulmonary function noted normal flow-volume 
curve. The diagnosis was that of  sequelae after chemotherapy 
damage. She was put on oral cyclophosphamide for 3 months 
without response and oral capecitabine for 3 months without 
response. Faced with the worsening cervicobrachial neuralgia in 
December 2012, an abdominothoracic and pelvic CT has been 
requested and showed D1 body compaction fracture with signifi-
cant lysis of  the posterior arch isolated without other associated 
visceral or bone lesions. In the lung, it revealed diffuse bilateral 
not septal thickening  in both upper lobes and a frosted glass ap-
pearance with retraction of  both lungs, thickened peri-pulmonary 
vascular bilateral diffuse evoking a post-treatment pulmonary 
fibrosis. CA 15-3 has reached 131.6 U/ml. She had the decom-
pressive laminectomy on 2 January 2013 with uneventful postop-
erative particularly in respiratory function. Histological study of  
bone and epidural samples showed epidural and bone metastasis 
of  poorly differentiated breast adenocarcinoma. A month later, 
she developed an inflammatory relapse at the right wall. Echocar-
diography made as part of  the evaluation of  the pre-chemo heart 
function showed an ejection fraction of  the left ventricle kept 
at 70%, a concentric left ventricular hypertrophy and especially 
the absence of  pulmonary hypertension stigma cardiac impact of  
prior post-chemotherapy lung damage.
Discussion
Docetaxel is an antineoplastic agent that inhibits the growth of  
tumors by inducing a stabilization of  microtubules and promot-
Figure 1. Chest x-ray of  the first staging in 2004 showing normal lungs.
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ing the inactivation of  bcl-2, thus sensitizing malignant cells to 
apoptotic stimuli [2]. It has proven its effectiveness in many solid 
tumors, including breast, stomach, ovaries, and NSCLC [1].
Hypersensitivity reactions are the most common toxicity associ-
ated with Docetaxel.
Pulmonary toxicity is more known with Paclitaxel [3, 4]. It usually 
occurs 48 hours after injection and disappears after a period of  
24-96 hours after initiation of  corticosteroid therapy.
There are few data in the literature associating interstitial pneu-
motistis (IP) with Docetaxel. Symptoms usually occur later and 
last longer. The evolution can be fatal as reported in some clinical 
cases. Read et al [5] reported 4 cases of  IP occurring 1-2 weeks 
after administration of  Docetaxel and have all used  mechanical 
ventilation due to acute respiratory failure.
The symptoms are variable and non-specific. Patients may present 
with a flu syndrome, a mild fever, dry cough and also dyspnea. 
Often these symptoms are interpreted as an infection and treated 
with broad spectrum antibiotics, without clinical improvement 
[6].
Chest X-ray can show ground-glass opacity. A chest CT scan is 
much more sensitive and typically shows reticular or nodular or 
disseminated bilateral reticulo-nodular infiltrates [7]. However, 
the diagnosis can not be made solely on imaging.
Breast cancer frequently gives pulmonary metastasis. It is there-
fore necessary to take a biopsy during bronchoscopy with analysis 
of  the aspirated fluid to eliminate a differential diagnosis [8].
IP induced by a drug is marked in the aspirated fluid by lympho-
cytic alveolitis, an increase in the number of  total cells, an increase 
in the proportion of  neutrophils and eosinophils, and a decreased 
CD4/CD8 count and in the trans- bronchial biopsy by edema and 
thickening of  the alveolar septa and alveolar and interstitial in-
filtration of  mononuclear cells with an intraluminal organization 
and aggregation of  alveolar macrophages [8]. In our case, the pa-
tient had no bronchoscopy but clinical and radiological evolution 
after the introduction of  high-dose corticosteroid therapy was in 
favor of  a toxic origin associated with Docetaxel.
IP usually occurs after the second cycle of  Docetaxel and can 
also occur between 1 and 9 treatment cycles. The mortality of  
Interstitial fibrosis is estimated at 40% [5]. In this case, the patient 
developed IP after the third cycle of  Docetaxel.
Pre-existing pulmonary emphysema (p: 0.016) or IP (P < 0.05), is 
accompanied by an increased risk of  developing pulmonary toxic-
ity. The authors concluded not to start Docetaxel if  they knew of  
pre-existing IP [9].
The symptoms rapidly increase for 1 to 2 days and can result in 
respiratory failure requiring mechanical ventilation [10].
The treatment of  choice is the administration of  corticosteroids 
type prednisolone at a dose of  30-60mg daily for 2 to 3 weeks and 
even 60-240mg daily for severe cases such as acute respiratory 
failure [10]. In our case, the patient used a high dose corticoster-
oid 120mg per day with gradual regression in two months.
Docetaxel is largely used for the treatment of  localized and meta-
static breast cancer. However, clinical and radiological monitoring 
of  respiratory function is recommended for the early diagnosis of  
IP and to prevent progression to an acute respiratory failure that 
can threaten the vital prognosis of  the patient. Particular caution 
should be taken for patients with pre-existing respiratory disease, 
in particular interstitial disease. An evaluation of  lung function 
should be recommended before starting treatment with taxanes 
to prevent aggravation of  their respiratory function. The search 
for IP predisposing factors should help in selecting patients who 
can not be exposed to taxanes in their oncology treatment plan.
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